Pivotal readout

FDA Prioritizes CMG901 Review

The FDA accepted CMG901's biologics license application and granted priority review for previously treated, locally advanced or metastatic CLDN18.2-positive gastric, gastroesophageal junction and esophageal adenocarcinomas; review completion is expected in the second quarter of 2027. In the phase 3 CLARITY-Gastric01 study, CMG901 reduced the risk of death versus investigator's choice of therapy by 53% in the third-line-or-later population and 42% in the second-line-or-later intention-to-treat population. A Chinese marketing application was accepted in October 2026, while AstraZeneca is also studying CMG901-based combinations in first-line disease.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call